Mayzent
| Chemical Name | siponimod |
| Dosage Form | Tablet (oral; 0.25 mg, 2 mg) |
| Drug Class | Modulators |
| System | Nervous |
| Company | Novartis |
| Approval Year | 2019 |
Indication
- Mayzent is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.